全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis

DOI: 10.1155/2013/792526

Full-Text   Cite this paper   Add to My Lib

Abstract:

Rheumatoid arthritis (RA) is considered as a connective tissue disease while ankylosing spondylitis (AS) is a prototype of spondyloarthritis. These diseases are seen concomitantly only very rarely. Also, rituximab has proven efficacy in the treatment of RA while its role in the treatment of AS is unclear. In this presentation, the concomitant presence of RA and AS in a 43-year-old male patient as well as the efficacy and safety of rituximab is discussed. Rituximab was given due to lack of response to treatment with anti-TNF-alpha. Evaluations made at the 6th and 12th months of treatment showed complete response for RA and partial response for AS. 1. Introduction Ankylosing spondylitis (AS) is a chronic inflammatory disease which primarily affects the sacroiliac joint and axial and peripheral joints [1]. It should typically be considered in young male patients with complaints of inflammatory lower back pain. Rheumatoid arthritis (RA), however, is a connective tissue disease which can lead to erosive arthritis and results in significant morbidity and mortality [2]. These diseases have different mechanisms of etiopathogenesis and they are rarely seen in the same person. Although the term “rheumatoid spondylitis” is used to describe the cervical involvement of RA, it can also be used for people who have both diseases concomitantly. Different disease-modifying antirheumatic drugs (DMARDs) are used for the treatment of these diseases [3]. The efficacy and safety of rituximab (RTX), in addition to DMARDs and anti-TNF-alpha drugs, have been proved in the treatment of RA. RTX is a chimeric monoclonal antibody targeted against CD20 which is used in RA patients who do not respond to treatment with one or more anti-TNF-alpha drugs [4]. Various studies have shown that it can be effective in other autoimmune diseases too [5, 6]. Anti-TNF-alpha drugs have revolutionized the treatment of AS by shaping the course and prognosis of the disease in the axial and peripheral involvement of AS [7]. However, disease activity canot be controlled with TNF-blockers in 50% of AS patients. Therefore, other treatment options are considered urgently in cases where anti-TNF-alpha drugs do not lead to a response and/or are contraindicated. Histological and MRI studies showed that the primary area of inflammation in AS is the cartilage and bone surface [8]. Mononuclear cell infiltration was detected in the cartilage and subchondral bone. Infiltrations, primarily of macrophages and T-cells, with specific immune response were identified in early and active sacroiliitis [9]. Surprisingly,

References

[1]  J. Braun and J. Sieper, “Ankylosing spondylitis,” The Lancet, vol. 369, no. 9570, pp. 1379–1390, 2007.
[2]  E. L. Matteson, M. D. Cohen, and D. L. Conn, “Rheumatoid arthritis: clinical features and systemic involvement,” in Rheumatology, J. H. Klippel and P. A. Dieppe, Eds., vol. 1, section 5.4.2, Mosby, London, UK, 1992.
[3]  J. Zochling, D. van der Heijde, R. Burgos-Vargas et al., “ASAS/EULAR recommendations for the management of ankylosing spondylitis,” Annals of the Rheumatic Diseases, vol. 65, no. 4, pp. 442–452, 2006.
[4]  P. Emery, R. Fleischmann, A. Filipowicz-Sosnowska, et al., “Rituximab in rheumatoid arthritis: a double-blind, placebo-controlled, dose-ranging trial,” Arthritis and Rheumatism, vol. 52, article 1917, 2005.
[5]  T. Jónsdóttir, I. Gunnarsson, A. Risselada, E. W. Henriksson, L. Klareskog, and R. F. Van Vollenhoven, “Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response,” Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. 330–334, 2008.
[6]  P. Seo, U. Specks, and K. A. Keogh, “Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations,” Journal of Rheumatology, vol. 35, no. 10, pp. 2017–2023, 2008.
[7]  D. Wendling and E. Toussirot, “Anti-TNF-α therapy in ankylosing spondylitis,” Expert Opinion on Pharmacotherapy, vol. 5, no. 7, pp. 1497–1507, 2004.
[8]  J. Braun, M. Bollow, L. Neure et al., “Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis,” Arthritis and Rheumatism, vol. 38, no. 4, pp. 499–505, 1995.
[9]  M. Bollow, T. Fischer, H. Rei?hauer et al., “Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis—cellularity correlates with the degree of enhancement detected by magnetic resonance imaging,” Annals of the Rheumatic Diseases, vol. 59, no. 2, pp. 135–140, 2000.
[10]  H. Appel, C. Loddenkemper, Z. Grozdanovic et al., “Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis,” Arthritis Research and Therapy, vol. 8, no. 5, article R143, 2006.
[11]  I.-H. Song, F. Heldmann, M. Rudwaleit et al., “Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial,” Arthritis and Rheumatism, vol. 62, no. 5, pp. 1290–1297, 2010.
[12]  C. Rodríguez-Escalera and A. Fernández-nebro, “The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B,” Rheumatology, vol. 47, no. 11, pp. 1732–1733, 2008.
[13]  G. Nocturne, M. Dougados, A. Constantin, C. Richez, J. Sellam, and A. Simon, “Lack of efficacy of rituximab in spondyloarthropathies:data of 8 patients prospectively followed in the French AIR (‘Auto-Immunity and Rituximab’) registry,” Annals of the Rheumatic Diseases, vol. 68, supplement 3, p. 626, 2009.
[14]  S. K. Schleenbecker and K. Strock Muller, “Improvement of refractory ankylosing spondylitis in response to rituximab: a case report,” Annals of the Rheumatic Diseases, vol. 67, supplement 2, p. 626, 2008.
[15]  D. Wendling, B. Augé, G. Streit, E. Toussirot, and S. Mathieu, “Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis,” Joint Bone Spine, vol. 75, no. 4, pp. 510–511, 2008.
[16]  S. Toussaint, S. Karrer, and S. Wassenberg, “Successful treatment of neutrophilic granulomatous dermatitis with rituximab in a patient with rheumatoid arthritis and spondylitis ancylosans: a case report,” Annals of the Rheumatic Diseases, vol. 67, supplement 2, p. 317, 2008.
[17]  T. D?rner and G. R. Burmester, “New approaches of B-cell-directed therapy: beyond rituximab,” Current Opinion in Rheumatology, vol. 20, no. 3, pp. 263–268, 2008.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133